Cynthia E Oliver

US Patent:

8007793, Aug 30, 2011

Filed:

Jun 16, 2010

Appl. No.:

12/817097

Inventors:

Cynthia N. Oliver - North Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
A61K 39/42

US Classification:

4241301, 4241411, 4241471, 4241591

Abstract:

The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

US Patent:

8460663, Jun 11, 2013

Filed:

May 25, 2012

Appl. No.:

13/481640

Inventors:

Cynthia N. Oliver - North Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
A61K 39/42

US Classification:

4241301, 4241411, 4241471

Abstract:

The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

US Patent:

8206951, Jun 26, 2012

Filed:

Jul 15, 2011

Appl. No.:

13/184455

Inventors:

Cynthia N. Oliver - North Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

C12N 5/07
C12N 5/16
C12P 21/04

US Classification:

435 7021, 435326, 435339

Abstract:

The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

US Patent:

20080286270, Nov 20, 2008

Filed:

Oct 1, 2007

Appl. No.:

11/906543

Inventors:

Cynthia N. Oliver - North Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

MedImmune, Inc. - Gaithersburg MD

International Classification:

A61K 39/395
A61P 11/00

US Classification:

4241331

Abstract:

The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

US Patent:

20220387579, Dec 8, 2022

Filed:

May 23, 2022

Appl. No.:

17/750612

Inventors:

- Gaithersburg MD, US
Ye LIU - Clarksville MD, US
Jing-Hui TIAN - Germantown MD, US
Michael J. MASSARE - Mt. Airy MD, US
Sarathi BODDAPATI - Germantown MD, US
Erica SHANE - McLean VA, US
Cynthia OLIVER - Potomac MD, US
Gregory GLENN - Poolesville MD, US

International Classification:

A61K 39/155
A61K 39/12
A61K 9/00
A61K 9/16
C12N 7/00

Abstract:

Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

US Patent:

20200101151, Apr 2, 2020

Filed:

Aug 20, 2019

Appl. No.:

16/545424

Inventors:

- Gaithersburg MD, US
Ye LIU - Clarksville MD, US
Jing-Hui TIAN - Germantown MD, US
Michael J. MASSARE - Mt. Airy MD, US
Sarathi BODDAPATI - Germantown MD, US
Erica SHANE - McLean VA, US
Cynthia OLIVER - Potomac MD, US
Gregory GLENN - Potomac MD, US

International Classification:

A61K 39/155
A61K 39/12
A61K 9/00
A61K 9/16
C12N 7/00

Abstract:

Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

US Patent:

20180133308, May 17, 2018

Filed:

Nov 21, 2017

Appl. No.:

15/819962

Inventors:

- Gaithersburg MD, US
Ye LIU - Clarksville MD, US
Jing-Hui TIAN - Germantown MD, US
Michael J. MASSARE - Mt. Airy MD, US
Sarathi BODDAPATI - Germantown MD, US
Erica SHANE - McLean VA, US
Cynthia OLIVER - Potomac MD, US
Gregory GLENN - Poolesville MD, US

Assignee:

Novavax, Inc. - Gaithersburg MD

International Classification:

A61K 39/155
A61K 9/16
C12N 7/00
A61K 9/00
A61K 39/00

Abstract:

Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

US Patent:

20170202948, Jul 20, 2017

Filed:

Sep 6, 2016

Appl. No.:

15/257436

Inventors:

- Gaithersburg MD, US
Ye Liu - Gaithersburg MD, US
Jing-Hui TIAN - Gaithersburg MD, US
Michael J. MASSARE - Gaithersburg MD, US
Sarathi BODDAPATI - Gaithersburg MD, US
Erica SHANE - Gaithersburg MD, US
Cynthia Oliver - Gaithersburg MD, US
Gregory GLENN - Gaithersburg MD, US

Assignee:

NOVAVAX, INC. - Gaithersburg MD

International Classification:

A61K 39/155
C12N 7/00
A61K 9/16
A61K 9/00

Abstract:

Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.